Main Menu

The FTC’s New Investigation of PBMs

Jessica Tinor
ABA Antitrust Law Section newsletter
February 2023

In June 2022, the Federal Trade Commission (FTC) launched an inquiry into the prescription drug middleman industry, requiring the largest pharmacy benefits managers (PBMs) to provide information about their business practices. In “The FTC’s New Investigation of PBMs,” Consultant Jessica Tinor provides some of the context necessary to understand the FTC’s concerns, specifically about rising consumer drug prices. She gives an overview of the prescription drug financing and distribution industry, explains the role of PMBs within that network, and discusses PBM incentives and how those could ultimately influence spending.

Read the article here (membership required).

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.